Among patients with acute myocardial infarction, 4 weekly infusions of a reconstituted infusible human apolipoprotein A-I, CSL112, are associated with a dose-dependent elevation of circulating apolipoprotein A-I and cholesterol efflux capacity without adverse hepatic or renal outcomes. Here, APOA1 is linked to myocardial infarction.